Elastography Market Size, Share, Growth, and Industry Analysis, By Type (Ultrasound Elastography, Magnetic Resonance Elastography (MRE), Others), By Application (Cancers, Musculoskeletal, Liver, Others), Regional Insights and Forecast to 2035

Elastography Market Overview

Global Elastography Market size is estimated at USD 3767.39 million in 2026 and is expected to reach USD 7222.99 million by 2035 at a 7.5% CAGR.

The elastography market is expanding rapidly as healthcare providers adopt non-invasive imaging to quantify tissue stiffness for liver, breast, thyroid, prostate, and musculoskeletal assessment. More than 65% of tertiary hospitals in developed economies now integrate some form of ultrasound or magnetic resonance elastography into diagnostic workflows. Over 40% of new premium ultrasound systems shipped globally include elastography capabilities, reflecting strong demand from radiology, hepatology, and oncology departments. Rising chronic liver disease prevalence, with over 1.5 billion affected worldwide, and increasing cancer screening volumes are driving procurement decisions, making elastography a core focus of many B2B Elastography Market Report and Elastography Industry Analysis initiatives.

In the USA, elastography adoption is particularly advanced, with over 70% of large academic medical centers and integrated delivery networks using ultrasound elastography for liver fibrosis staging and oncology imaging. More than 55% of new high-end ultrasound installations in the U.S. feature shear-wave or strain elastography modules. Around 35% of liver assessments in major hepatology centers now rely on elastography instead of biopsy, significantly reducing invasive procedures. Breast imaging programs report elastography use in nearly 30% of complex lesion evaluations. These patterns are central to U.S.-focused Elastography Market Analysis, Elastography Market Size evaluation, and B2B Elastography Market Research Report demand.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Over 60% of demand is driven by rising chronic liver disease and cancer screening volumes, with 45% of hospitals prioritizing non-invasive stiffness assessment technologies.
• Major Market Restraint: Approximately 35% of potential buyers cite high capital costs, while 28% report limited trained operators as a barrier to elastography deployment.
• Emerging Trends: Around 40% of new installations integrate AI-assisted quantification, and 32% of providers adopt portable elastography systems for point-of-care and outpatient settings.
• Regional Leadership: North America accounts for roughly 38% of global elastography installations, Europe 29%, Asia-Pacific 25%, and other regions collectively about 8% of share.
• Competitive Landscape: The top five vendors control nearly 72% of the elastography market share, while smaller regional players and niche innovators account for the remaining 28%.
• Market Segmentation: Ultrasound elastography represents about 68% of installed systems, magnetic resonance elastography 22%, and other modalities and hybrids nearly 10% of deployments.
• Recent Development: In the last cycle, over 45% of new product launches focused on liver applications, 30% on oncology, and 25% on musculoskeletal and multi-organ solutions.

Elastography Market Latest Trends

The elastography market is shaped by several latest trends that B2B buyers track closely in Elastography Market Trends and Elastography Market Outlook studies. Hospitals and imaging centers are increasingly shifting from qualitative to quantitative elastography, with more than 55% of new systems offering standardized stiffness values in kilopascals. Around 48% of radiology departments report using elastography as a first-line tool for liver fibrosis assessment, reducing biopsy rates by up to 35%. Integration with PACS and enterprise imaging platforms is now present in over 60% of newly installed systems, supporting multi-site networks and tele-radiology workflows.

Another key trend in Elastography Market Insights is the rapid rise of multi-organ elastography protocols. Approximately 40% of advanced centers use elastography for both liver and breast, while 25% extend use to thyroid and prostate. In musculoskeletal imaging, adoption has grown to nearly 20% of sports medicine and orthopedic imaging practices. Vendor-neutral software and AI-based post-processing tools are being adopted by about 30% of high-volume centers, enabling cross-vendor comparison and standardized reporting. These trends are central to Elastography Market Growth strategies and long-term Elastography Market Forecast models for OEMs and healthcare investors.

Elastography Market Dynamics

DRIVER

"Rising burden of chronic liver disease and cancer"

The primary driver of elastography market growth is the rising global burden of chronic liver disease and cancer, which directly influences B2B Elastography Market Growth and Elastography Industry Report assessments. More than 25% of the world’s population is estimated to have non-alcoholic fatty liver disease, and over 20% of these patients are at risk of progressive fibrosis. Around 70% of hepatology guidelines now recommend non-invasive elastography-based staging in routine practice. In oncology, breast cancer accounts for nearly 12% of all new cancer cases globally, and up to 30% of complex breast lesions in advanced centers are evaluated with elastography. These clinical pressures push over 50% of tertiary hospitals to prioritize elastography-enabled ultrasound or MRI in their capital equipment plans, significantly influencing Elastography Market Share and procurement decisions.

RESTRAINTS

"High equipment cost and training gaps"

A major restraint highlighted in Elastography Market Analysis is the high upfront cost of elastography-capable systems and the shortage of trained operators. Approximately 35% of mid-sized hospitals in emerging markets delay elastography adoption due to budget constraints, while 30% of private imaging centers report difficulty justifying premium system upgrades. Training gaps are also significant: nearly 40% of radiologists and sonographers in community settings have limited hands-on experience with advanced elastography modes. In some regions, fewer than 25% of facilities have standardized elastography protocols, leading to inconsistent results and underutilization. These factors collectively slow down elastography market penetration, particularly in price-sensitive geographies, and constrain the full realization of Elastography Market Opportunities.

OPPORTUNITY

"Expansion into point-of-care and outpatient settings"

A key opportunity in the elastography market lies in expanding into point-of-care, ambulatory, and outpatient environments, a focus area in many Elastography Market Research Reports. Portable and cart-based ultrasound systems with elastography now represent about 35% of new elastography-capable ultrasound shipments. Around 28% of liver clinics and metabolic centers are adopting compact elastography devices for on-site fibrosis assessment, reducing referrals and improving patient throughput by nearly 20%. In primary care and endocrinology, thyroid elastography is gaining traction, with adoption in roughly 18% of high-volume practices. As value-based care models spread, more than 40% of integrated delivery networks plan to shift diagnostics closer to patients, creating strong demand for cost-effective elastography solutions and expanding the addressable Elastography Market Size across new care settings.

CHALLENGE

"Standardization, reimbursement, and interoperability issues"

One of the most persistent challenges in the elastography market, frequently cited in Elastography Industry Analysis, is the lack of full standardization and consistent reimbursement. Different vendors use varying elastography algorithms and measurement scales, and nearly 45% of clinicians report difficulty comparing results across platforms. In some countries, reimbursement coverage for elastography is partial or absent, affecting up to 50% of potential procedures and limiting utilization rates. Interoperability gaps also persist: about 30% of facilities struggle to integrate elastography data seamlessly into existing PACS and reporting systems. These issues can reduce clinician confidence, slow protocol adoption, and complicate multi-center research, thereby constraining the pace of Elastography Market Outlook improvements despite strong clinical evidence.

Elastography Market Segmentation

The elastography market is segmented by type and application, enabling detailed Elastography Market Report and Elastography Market Segmentation analysis for B2B buyers. By type, the market is divided into ultrasound elastography, magnetic resonance elastography (MRE), and other emerging modalities. By application, elastography is used across cancers, musculoskeletal disorders, liver diseases, and other organ systems such as thyroid and prostate. Ultrasound-based solutions account for the majority of installed systems, while MRE is gaining traction in specialized centers. Application-wise, liver and oncology together represent more than 60% of procedure volumes, shaping Elastography Market Share and investment priorities.

Download Free Sample to learn more about this report.

BY TYPE

Ultrasound Elastography: Ultrasound elastography dominates the elastography market, accounting for approximately 68% of global installations and more than 70% of routine elastography procedures. It is widely adopted in radiology, hepatology, breast imaging, and thyroid clinics due to its lower cost and broad availability. Over 60% of premium and high-end ultrasound systems shipped in recent years include shear-wave or strain elastography capabilities. In liver applications, ultrasound elastography is used in nearly 80% of non-invasive fibrosis assessments, while in breast imaging it supports around 25–30% of complex lesion evaluations. Its portability and real-time imaging make it the preferred choice for point-of-care and outpatient settings, and more than 40% of new elastography-capable devices are compact or portable ultrasound units, reinforcing its central role in Elastography Market Growth.

Magnetic Resonance Elastography (MRE): Magnetic resonance elastography represents about 22% of the elastography market by installed base but commands a disproportionately high share of advanced liver and research applications. Approximately 30% of large academic medical centers and specialized liver institutes use MRE for detailed fibrosis staging and diffuse liver disease characterization. MRE offers whole-organ coverage and high reproducibility, with some studies reporting diagnostic accuracy above 90% for advanced fibrosis, which is reflected in its strong presence in Elastography Market Insights for high-end imaging. However, MRE requires MRI infrastructure, and only around 20–25% of MRI scanners in major hospitals are currently equipped with MRE capabilities. Despite this, MRE procedures account for nearly 15% of elastography-based liver assessments in top-tier centers, and its share is gradually increasing as more MRI vendors integrate elastography sequences.

Others: Other elastography modalities, including endoscopic, transoral, and emerging hybrid or vendor-specific technologies, collectively account for roughly 10% of the elastography market. These solutions are often used in niche or advanced applications, such as endoscopic ultrasound elastography for pancreatic and gastrointestinal lesions, which is employed in about 10–15% of complex GI oncology cases in high-volume centers. Some novel systems integrate elastography into specialized probes or interventional tools, targeting intraoperative or minimally invasive procedures. Although their current share is smaller compared with ultrasound and MRE, these modalities are growing steadily, with adoption rates in certain subspecialties increasing by 8–12 percentage points over recent cycles. Their role is particularly important in differentiated Elastography Market Opportunities, where vendors seek high-value, procedure-specific use cases.

BY APPLICATION

Cancers: Oncology is one of the largest and fastest-growing application segments in the elastography market, frequently highlighted in Elastography Market Trends and Elastography Industry Report documents. Cancer-related elastography procedures account for roughly 35–40% of total elastography usage. In breast imaging, elastography is used in about 25–30% of complex lesion assessments, helping differentiate benign from malignant masses and reducing unnecessary biopsies by up to 20–25% in some centers. Thyroid cancer workups increasingly incorporate elastography, with adoption in nearly 20% of high-volume endocrine and radiology practices. Prostate elastography, though still emerging, is used in around 10–15% of advanced urology and radiology centers for targeted biopsy guidance. Overall, more than 45% of tertiary oncology centers in developed markets have at least one elastography-capable system, and multi-organ oncology protocols are being implemented in approximately 30% of comprehensive cancer centers, driving sustained Elastography Market Growth in this segment.

Musculoskeletal: Musculoskeletal (MSK) applications represent a growing share of the elastography market, currently estimated at around 15–18% of total procedure volumes. Sports medicine, orthopedics, and rheumatology practices are increasingly using elastography to evaluate tendons, ligaments, and muscles for stiffness, tears, and chronic overuse injuries. In high-performance sports centers, up to 25% of advanced imaging assessments for soft-tissue injuries now include elastography. Around 20% of radiology departments with MSK subspecialty services report routine use of elastography for Achilles tendon, rotator cuff, and hamstring evaluations. In rheumatology, elastography is being explored for early detection of inflammatory changes in tendons and fascia, with pilot adoption in approximately 10% of specialized clinics. As awareness grows, MSK elastography is expected to capture a larger portion of Elastography Market Share, particularly in private imaging centers and sports medicine networks seeking differentiation.

Liver: Liver applications are the single largest segment in the elastography market, accounting for roughly 40–45% of all elastography procedures and forming the backbone of many Elastography Market Analysis and Elastography Market Forecast models. Non-alcoholic fatty liver disease and viral hepatitis drive high demand for non-invasive fibrosis staging. In advanced hepatology centers, more than 70% of fibrosis assessments rely on elastography rather than biopsy. Ultrasound elastography is used in nearly 80% of these cases, while MRE accounts for about 15–20% in specialized institutions. Screening programs in high-prevalence regions have led to elastography adoption in over 50% of large public hospitals and liver clinics. In some countries, national guidelines recommend elastography as the primary tool for staging chronic liver disease, contributing to procedure volume growth of more than 20 percentage points over recent cycles. This dominant liver segment is central to Elastography Market Size and long-term investment planning.

Others: Other applications, including thyroid, prostate, vascular, and pediatric uses, collectively represent around 10–12% of elastography procedures but are expanding steadily. Thyroid elastography is used in approximately 20–25% of thyroid nodule evaluations in advanced endocrine and radiology practices, helping reduce unnecessary biopsies by up to 15–20%. Prostate elastography, integrated into transrectal ultrasound workflows, is adopted in about 10–15% of high-end urology centers for targeted biopsy and lesion characterization. Vascular elastography is being explored in research settings for plaque characterization, with early adoption in fewer than 5% of specialized cardiovascular centers. Pediatric elastography, particularly for liver and musculoskeletal conditions, is used in roughly 8–10% of large pediatric hospitals. These diverse applications broaden the clinical footprint of elastography and create new Elastography Market Opportunities across subspecialties.

Elastography Market Regional Outlook

Regionally, the elastography market is led by North America with approximately 38% share, followed by Europe at around 29%, Asia-Pacific at about 25%, and the Middle East & Africa plus other regions collectively near 8%. North America’s dominance is driven by high imaging infrastructure penetration and early technology adoption. Europe benefits from strong public healthcare systems and guideline-driven liver and oncology programs. Asia-Pacific is the fastest-expanding region in terms of installed base, with elastography adoption rising rapidly in China, Japan, South Korea, and India. The Middle East & Africa region, while smaller at present, is experiencing steady growth as tertiary care and private imaging networks expand, reshaping the global Elastography Market Outlook and regional Elastography Market Share distribution.

Download Free Sample to learn more about this report.

NORTH AMERICA

North America holds the leading position in the elastography market, accounting for roughly 38% of global share. The United States alone represents more than 80% of the regional elastography installed base, with Canada contributing the remaining portion. Over 70% of large academic medical centers and integrated delivery networks in the region have elastography-capable ultrasound or MRI systems. In liver applications, elastography is used in nearly 65–70% of non-invasive fibrosis assessments across major hepatology centers. Breast and thyroid elastography adoption is also strong, with usage in about 30% of complex breast lesion evaluations and 20–25% of thyroid nodule assessments in advanced practices. Private imaging centers and outpatient clinics account for approximately 40% of elastography procedure volumes, reflecting the region’s strong ambulatory care focus. Reimbursement coverage for key elastography indications is available in a majority of U.S. states and Canadian provinces, supporting utilization rates that are 20–30 percentage points higher than many other regions. These dynamics make North America a focal point in Elastography Market Research Reports and vendor go-to-market strategies, with high replacement and upgrade cycles driving continuous Elastography Market Growth.

EUROPE

Europe represents around 29% of the global elastography market share, supported by robust public healthcare systems and strong guideline-based adoption. Western Europe accounts for nearly 75% of the regional installed base, with countries such as Germany, France, the United Kingdom, Italy, and Spain leading in elastography deployment. In many European hepatology guidelines, elastography is recommended as a first-line tool for liver fibrosis staging, resulting in elastography use in approximately 60–65% of chronic liver disease assessments in major centers. Breast elastography is integrated into about 25–30% of advanced breast imaging programs, while thyroid elastography is used in roughly 20% of high-volume endocrine clinics. Central and Eastern Europe, though representing a smaller portion of the market, are experiencing faster growth, with elastography adoption increasing by more than 10–15 percentage points in some countries over recent cycles. Public tenders and regional procurement initiatives account for nearly 50% of elastography system purchases, influencing vendor competition and pricing. Europe’s emphasis on evidence-based practice and multi-center research makes it a key region for Elastography Market Insights, clinical validation, and technology standardization efforts.

ASIA-PACIFIC

Asia-Pacific accounts for approximately 25% of the global elastography market share and is one of the most dynamic regions in terms of growth in installed base and procedure volumes. China, Japan, South Korea, and India collectively represent more than 70% of the regional elastography deployments. In high-prevalence liver disease countries, such as China, elastography is increasingly used in large screening and management programs, with adoption in over 50% of tertiary hospitals and major liver centers. Japan and South Korea have high imaging infrastructure density, and elastography is integrated into about 60% of premium ultrasound systems in leading hospitals. Private hospitals and diagnostic chains in India and Southeast Asia are rapidly adding elastography capabilities, with adoption rates in some urban centers rising by 15–20 percentage points over recent cycles. Oncology and thyroid applications are also expanding, with elastography used in approximately 20–25% of complex breast and thyroid evaluations in advanced facilities. While reimbursement and budget constraints remain uneven across countries, the region’s large patient base and rising healthcare investments make Asia-Pacific a central focus of Elastography Market Forecast and long-term Elastography Market Opportunities for global and regional vendors.

MIDDLE EAST & AFRICA

The Middle East & Africa region currently represents about 8% of the global elastography market share but is experiencing steady expansion as healthcare infrastructure improves. The Gulf Cooperation Council countries, including Saudi Arabia, the United Arab Emirates, and Qatar, account for more than 60% of the regional elastography installed base. In these markets, tertiary hospitals and private specialty centers are early adopters, with elastography-capable ultrasound systems present in approximately 50–55% of large imaging departments. Liver disease and obesity-related conditions drive demand, with elastography used in around 40% of non-invasive fibrosis assessments in leading centers. In North Africa and Sub-Saharan Africa, adoption is more concentrated in major urban hospitals and private diagnostic networks, which together account for nearly 70% of regional elastography procedures. Limited reimbursement and budget constraints mean that many facilities prioritize multi-purpose ultrasound systems with elastography as an added feature, rather than standalone solutions. Despite these challenges, procedure volumes are growing by more than 10 percentage points in some markets, and international collaborations and training programs are gradually increasing clinician familiarity. This region is increasingly included in Elastography Market Outlook and Elastography Industry Analysis as vendors seek new growth corridors beyond mature markets.

List of Key Elastography Market Companies

• Siemens-healthineers
• Hitachi Medical Systems
• Supersonic Imagine
• Echosens
• ESAOTE SPA
• Resoundant, Inc
• Michigan Medicine
• Mayo Clinic
• Second Affiliated Hospital of Sun Yat-Sen University
• Qscan Radiology Clinics
• Canon Medical Systems Corporation
• Esaote SpA
• Fujifilm Corporation
• GE Healthcare
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Hologic, Inc
• Koninklijke Philips N.V.
• Sandhill Scientific
• FibroScan

Top Two Companies with Highest Share

• GE Healthcare: Holds approximately 18% global elastography share, driven by broad ultrasound portfolio and strong hospital relationships.
• Siemens-healthineers: Commands around 16% share, supported by integrated ultrasound and MRI elastography platforms across major regions.

Investment Analysis and Opportunities

Investment activity in the elastography market is intensifying as hospitals, imaging centers, and private equity groups target high-growth diagnostic segments. Approximately 55% of large hospital systems in developed markets plan to upgrade or expand elastography-capable ultrasound or MRI systems within their next capital cycle. In emerging markets, around 40% of private diagnostic chains indicate elastography as a priority feature in new imaging investments. Venture and strategic investors are increasingly backing AI-enabled elastography software and workflow tools, with more than 30% of recent imaging AI deals involving some form of quantitative tissue characterization. These patterns are central to Elastography Market Analysis and long-term Elastography Market Forecast models.

From an opportunity standpoint, liver and oncology applications capture nearly 60% of investor interest, while musculoskeletal and thyroid segments account for about 25%. Point-of-care and portable elastography solutions represent roughly 35% of new product-focused investments, reflecting a shift toward decentralized care. Cloud-based analytics and vendor-neutral elastography platforms are emerging as attractive niches, with adoption interest from nearly 45% of multi-site imaging networks. Overall, more than 50% of healthcare executives surveyed in recent Elastography Market Research Reports view elastography as a strategic imaging capability with strong return-on-investment potential over the medium term, particularly when integrated into comprehensive chronic disease management programs.

New Products Development

New product development in the elastography market is heavily focused on improving accuracy, usability, and integration, shaping the competitive landscape described in many Elastography Industry Reports. Around 45% of recent product launches feature enhanced shear-wave elastography with improved penetration and frame rates, enabling better assessment in obese and difficult-to-scan patients. Approximately 35% of new systems incorporate AI-assisted lesion characterization and automated stiffness quantification, reducing operator variability by up to 20–25% in some clinical evaluations. Multi-parametric imaging, combining elastography with contrast-enhanced ultrasound or advanced MRI sequences, is present in about 25% of high-end product lines, targeting complex oncology and liver cases.

User-centric design is another priority, with nearly 40% of new elastography-capable ultrasound systems offering simplified workflows, pre-set protocols, and automated reporting templates. Portable and handheld devices with elastography functions now represent about 30% of new introductions in certain price segments, addressing point-of-care and outpatient demand. Interoperability enhancements are also evident: more than 50% of new platforms emphasize seamless integration with PACS, RIS, and enterprise imaging systems, supporting standardized Elastography Market Insights across multi-site networks. These innovations collectively expand Elastography Market Opportunities, enabling vendors to target both high-end academic centers and cost-sensitive community providers with differentiated solutions.

Five Recent Developments

• Advanced AI-Driven Liver Elastography Suite: In 2025, a leading vendor introduced an AI-enhanced liver elastography package that reduced measurement variability by approximately 22% and cut average exam time by 18%, significantly improving throughput in high-volume hepatology centers.
• Portable Point-of-Care Elastography System: A major ultrasound manufacturer launched a compact elastography-enabled device in 2025, targeting outpatient clinics and mobile services, with early adopters reporting a 28% increase in liver and thyroid assessments outside hospital settings.
• Multi-Organ Oncology Elastography Platform: In 2025, a new software upgrade enabled integrated breast, thyroid, and prostate elastography workflows on a single platform, leading to a 30% rise in multi-organ oncology protocols in participating cancer centers.
• Expanded MRE Capability on Mid-Range MRI Scanners: A prominent MRI vendor rolled out MRE sequences to mid-range systems in 2025, increasing the proportion of MRI units with elastography capability from 24% to 33% across its installed base within one year.
• Cloud-Based Elastography Analytics Service: In 2025, a cloud analytics provider launched a vendor-neutral elastography reporting solution, with early deployments across multi-site networks showing a 26% improvement in reporting consistency and a 15% reduction in manual data entry time.

Report Coverage Of Elastography Market

The Elastography Market Report provides comprehensive coverage of market size, segmentation, and competitive dynamics across ultrasound elastography, magnetic resonance elastography, and emerging modalities. It analyzes global and regional Elastography Market Share, with detailed breakdowns for North America, Europe, Asia-Pacific, and the Middle East & Africa, collectively accounting for 100% of the market. The report quantifies the relative contribution of key applications, showing liver and oncology representing nearly 60% of procedure volumes, musculoskeletal around 15–18%, and other applications approximately 10–12%. It also assesses the concentration of market power, noting that the top five vendors control about 72% of the installed base.

In addition, the Elastography Market Research Report evaluates key drivers, restraints, opportunities, and challenges, supported by percentage-based data on adoption rates, utilization patterns, and investment intentions. It includes B2B-focused Elastography Market Insights on purchasing criteria, with more than 55% of buyers prioritizing image quality and quantification accuracy, and around 40% emphasizing interoperability and workflow integration. The report also covers technology trends, such as AI integration in roughly 40% of new systems and the growing share of portable devices at about 30% of recent launches. This level of detail supports strategic planning, product development, and capital budgeting decisions for healthcare providers, manufacturers, and investors engaged in the elastography market.